NCAM1 and multidrug-resistant tuberculosis: In 1977, Johnson et al. reported that daily rhuIL-2 treatment could increase the mean number of circulating natural killer (NK) cells (CD16+/CD56+) at the post-study timepoint, compared to the baseline NK cell numbers in the MDR-TB patients [18].